Home » Newsletters » BioWorld Science

BioWorld Science

March 14, 2016

View Archived Issues

Medigene cleared to advance DC vaccine trial to phase II

Prous Institute announces new research collaboration agreement with Broad Institute

MIN-202 well tolerated and improves symptoms of depression in phase I study

First patient dosed in phase I trial of ADCT-402 in patients with B-NHL

Grant supports esophageal cancer screening study at Fred Hutchinson Cancer Research Center

FDA approves Xalkori for ROS1-positive metastatic NSCLC

Takeda Pharmaceutical patents HDAC6 inhibitors

Award supports Biosceptre's preclinical work in kidney and lung cancers

Astellas Pharma discloses muscarinic M3 receptor PAMs

EpiTherapeutics describes lysine-specific demethylase inhibitors

Sunnylife Pharma presents 5-HT2C receptor agonists

Oncology Venture initiates APO-010 screening study

University of Virginia reports RUNX1 inhibitors

First human data for HT-3951

BMS reports data on BMS-986142

AbbVie initiates phase III clinical studies to evaluate ABT-493/ABT-530

Efficacy of endoxifen in bipolar disorder

GNI submits IND to initiate clinical trials of F-351 for liver fibrosis

Roche launches DISCOVERY Yellow Kit

FDA approves Spectrum Pharmaceuticals' Evomela

Ozgene knock-in mouse model to help advance diabetes research at University of Auckland

MSD KK files application for approval of oral agents for chronic hepatitis C in Japan

FDA grants orphan drug designation to dianhydrogalacticol for the treatment of medulloblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...